Zydus Lifesciences Limited (ZYDUSLIFE) - Net Assets
Based on the latest financial reports, Zydus Lifesciences Limited (ZYDUSLIFE) has net assets worth Rs280.90 Billion INR (≈ $3.04 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs468.97 Billion ≈ $5.07 Billion USD) and total liabilities (Rs188.07 Billion ≈ $2.03 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Zydus Lifesciences Limited to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs280.90 Billion |
| % of Total Assets | 59.9% |
| Annual Growth Rate | 20.38% |
| 5-Year Change | 76.55% |
| 10-Year Change | 380.35% |
| Growth Volatility | 8.84 |
Zydus Lifesciences Limited - Net Assets Trend (2004–2025)
This chart illustrates how Zydus Lifesciences Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Zydus Lifesciences Limited stock valuation.
Annual Net Assets for Zydus Lifesciences Limited (2004–2025)
The table below shows the annual net assets of Zydus Lifesciences Limited from 2004 to 2025. Also explore net asset momentum of Zydus Lifesciences Limited to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs263.58 Billion ≈ $2.85 Billion |
+19.26% |
| 2024-03-31 | Rs221.02 Billion ≈ $2.39 Billion |
+12.26% |
| 2023-03-31 | Rs196.88 Billion ≈ $2.13 Billion |
+3.33% |
| 2022-03-31 | Rs190.54 Billion ≈ $2.06 Billion |
+27.62% |
| 2021-03-31 | Rs149.30 Billion ≈ $1.61 Billion |
+27.49% |
| 2020-03-31 | Rs117.10 Billion ≈ $1.27 Billion |
+0.27% |
| 2019-03-31 | Rs116.79 Billion ≈ $1.26 Billion |
+30.71% |
| 2018-03-31 | Rs89.36 Billion ≈ $966.34 Million |
+25.57% |
| 2017-03-31 | Rs71.16 Billion ≈ $769.58 Million |
+29.68% |
| 2016-03-31 | Rs54.87 Billion ≈ $593.43 Million |
+24.13% |
| 2015-03-31 | Rs44.20 Billion ≈ $478.06 Million |
+23.36% |
| 2014-03-31 | Rs35.83 Billion ≈ $387.52 Million |
+16.96% |
| 2013-03-31 | Rs30.64 Billion ≈ $331.34 Million |
+15.01% |
| 2012-03-31 | Rs26.64 Billion ≈ $288.10 Million |
+19.01% |
| 2011-03-31 | Rs22.38 Billion ≈ $242.07 Million |
+34.22% |
| 2010-03-31 | Rs16.68 Billion ≈ $180.36 Million |
+32.57% |
| 2009-03-31 | Rs12.58 Billion ≈ $136.05 Million |
+16.31% |
| 2008-03-31 | Rs10.82 Billion ≈ $116.97 Million |
+22.95% |
| 2007-03-31 | Rs8.80 Billion ≈ $95.14 Million |
+25.74% |
| 2006-03-31 | Rs7.00 Billion ≈ $75.66 Million |
+17.90% |
| 2005-03-31 | Rs5.93 Billion ≈ $64.17 Million |
+10.63% |
| 2004-03-31 | Rs5.36 Billion ≈ $58.01 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zydus Lifesciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 34342.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs247.99 Billion | 103.53% |
| Common Stock | Rs1.01 Billion | 0.42% |
| Other Comprehensive Income | Rs-9.46 Billion | -3.95% |
| Total Equity | Rs239.53 Billion | 100.00% |
Zydus Lifesciences Limited Competitors by Market Cap
The table below lists competitors of Zydus Lifesciences Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PRADA S.P.A.UNS.ADR/2 EO1
F:PRP0
|
$11.97 Billion |
|
One 97 Communications Limited
NSE:PAYTM
|
$11.98 Billion |
|
Samsung Heavy Industries
KO:010140
|
$11.98 Billion |
|
Industrivarden AB ser. A
ST:INDU-A
|
$11.99 Billion |
|
Smith & Nephew SNATS Inc
NYSE:SNN
|
$11.96 Billion |
|
Manhattan Associates Inc
NASDAQ:MANH
|
$11.95 Billion |
|
KERRY GRP PLC ADR/1EO-12
F:KRZA
|
$11.95 Billion |
|
YTL Power International Bhd
KLSE:6742
|
$11.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zydus Lifesciences Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 198,295,000,000 to 239,531,000,000, a change of 41,236,000,000 (20.8%).
- Net income of 45,255,000,000 contributed positively to equity growth.
- Dividend payments of 3,025,000,000 reduced retained earnings.
- Other comprehensive income decreased equity by 690,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs45.26 Billion | +18.89% |
| Dividends Paid | Rs3.02 Billion | -1.26% |
| Other Comprehensive Income | Rs-690.00 Million | -0.29% |
| Other Changes | Rs-304.00 Million | -0.13% |
| Total Change | Rs- | 20.80% |
Book Value vs Market Value Analysis
This analysis compares Zydus Lifesciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.62x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 96.51x to 4.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | Rs11.39 | Rs1099.00 | x |
| 2005-03-31 | Rs12.60 | Rs1099.00 | x |
| 2006-03-31 | Rs7.42 | Rs1099.00 | x |
| 2007-03-31 | Rs9.19 | Rs1099.00 | x |
| 2008-03-31 | Rs11.27 | Rs1099.00 | x |
| 2009-03-31 | Rs12.07 | Rs1099.00 | x |
| 2010-03-31 | Rs15.91 | Rs1099.00 | x |
| 2011-03-31 | Rs21.21 | Rs1099.00 | x |
| 2012-03-31 | Rs25.14 | Rs1099.00 | x |
| 2013-03-31 | Rs28.76 | Rs1099.00 | x |
| 2014-03-31 | Rs33.59 | Rs1099.00 | x |
| 2015-03-31 | Rs41.53 | Rs1099.00 | x |
| 2016-03-31 | Rs52.28 | Rs1099.00 | x |
| 2017-03-31 | Rs67.99 | Rs1099.00 | x |
| 2018-03-31 | Rs85.42 | Rs1099.00 | x |
| 2019-03-31 | Rs101.45 | Rs1099.00 | x |
| 2020-03-31 | Rs101.35 | Rs1099.00 | x |
| 2021-03-31 | Rs126.91 | Rs1099.00 | x |
| 2022-03-31 | Rs166.05 | Rs1099.00 | x |
| 2023-03-31 | Rs172.46 | Rs1099.00 | x |
| 2024-03-31 | Rs195.96 | Rs1099.00 | x |
| 2025-03-31 | Rs238.02 | Rs1099.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zydus Lifesciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.89%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.47%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 1.55x
- Recent ROE (18.89%) is below the historical average (22.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 24.81% | 11.13% | 0.89x | 2.50x | Rs794.60 Million |
| 2005 | 20.48% | 9.77% | 0.91x | 2.29x | Rs621.60 Million |
| 2006 | 21.81% | 10.54% | 0.92x | 2.25x | Rs825.10 Million |
| 2007 | 27.01% | 13.09% | 0.89x | 2.32x | Rs1.47 Billion |
| 2008 | 24.25% | 11.37% | 0.88x | 2.42x | Rs1.51 Billion |
| 2009 | 24.54% | 10.59% | 0.85x | 2.74x | Rs1.80 Billion |
| 2010 | 31.02% | 13.70% | 0.99x | 2.30x | Rs3.42 Billion |
| 2011 | 32.74% | 15.92% | 0.98x | 2.10x | Rs4.94 Billion |
| 2012 | 25.36% | 12.82% | 0.80x | 2.48x | Rs3.95 Billion |
| 2013 | 22.19% | 10.35% | 0.86x | 2.50x | Rs3.59 Billion |
| 2014 | 23.37% | 11.16% | 0.90x | 2.32x | Rs4.60 Billion |
| 2015 | 27.06% | 13.30% | 0.96x | 2.13x | Rs7.25 Billion |
| 2016 | 36.13% | 20.51% | 0.94x | 1.87x | Rs13.99 Billion |
| 2017 | 21.38% | 15.87% | 0.62x | 2.19x | Rs7.92 Billion |
| 2018 | 20.31% | 14.92% | 0.66x | 2.07x | Rs9.01 Billion |
| 2019 | 17.80% | 14.04% | 0.56x | 2.26x | Rs8.10 Billion |
| 2020 | 11.34% | 8.26% | 0.60x | 2.28x | Rs1.39 Billion |
| 2021 | 16.42% | 14.81% | 0.60x | 1.84x | Rs8.34 Billion |
| 2022 | 26.40% | 29.70% | 0.54x | 1.64x | Rs27.87 Billion |
| 2023 | 11.19% | 11.37% | 0.67x | 1.47x | Rs2.09 Billion |
| 2024 | 19.46% | 19.74% | 0.67x | 1.48x | Rs18.77 Billion |
| 2025 | 18.89% | 19.47% | 0.62x | 1.55x | Rs21.30 Billion |
Industry Comparison
This section compares Zydus Lifesciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $28,018,515,021
- Average return on equity (ROE) among peers: 13.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zydus Lifesciences Limited (ZYDUSLIFE) | Rs280.90 Billion | 24.81% | 0.67x | $11.96 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $354.09 Million | 3.07% | 2.25x | $30.30 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.00 Billion | 13.75% | 2.66x | $420.83 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $13.86 Billion | -0.01% | 0.47x | $773.91 Million |
| Abbott India Limited (ABBOTINDIA) | $3.05 Billion | 19.95% | 0.50x | $6.00 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $25.99 Billion | 18.00% | 0.28x | $4.74 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $33.31 Billion | 7.66% | 0.64x | $1.27 Billion |
| Alkem Laboratories Limited (ALKEM) | $12.05 Billion | 19.50% | 0.29x | $6.67 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $964.67 Million | 9.99% | 0.49x | $153.02 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $50.67 Billion | 22.63% | 0.32x | $1.75 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $138.92 Billion | 17.02% | 0.90x | $10.33 Billion |
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, con… Read more